A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 62744
NMA SSA Reference Number: SSA/62744/MonH-2020-219009(v1)
Monash Health Reference: RES-20-0000-199A
Effective start/end date30/07/2029/07/25


  • clinical trial
  • treatment efficacy
  • treatment safety
  • ovarian cancer
  • fallopian tube cancer